Pier Mannuccio Mannucci

List of Publications by Year
in descending order

323 papers	18,066 citations	14655 66 h-index	15732 125 g-index

329 all docs	329 docs citations	329 times ranked	13763 citing authors

#	Article	IF	Citations
1	Traffic-related air pollution and the coronavirus pandemia: shadows and lights. European Journal of Preventive Cardiology, 2022, 28, e3-e5.	1.8	7
2	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: comment. Internal and Emergency Medicine, 2022, 17, 299-302.	2.0	5
3	Clinical risk scores for the early prediction of severe outocomes in patients hospitalized for COVID-19: comment. Internal and Emergency Medicine, 2022, 17, 303-306.	2.0	2
4	Thrombotic thrombocytopenic purpura and other immune-mediated blood disorders following vaccination against SARS-CoV-2. Haematologica, 2022, 107, 785-786.	3.5	2
5	Integrated care: easy in theory, harder in practice?. Internal and Emergency Medicine, 2022, 17, 3-6.	2.0	6
6	Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors. Haemophilia, 2022, 28, 55-64.	2.1	7
7	Cardiovascular health and ambient air pollution: lower is not enough. European Journal of Preventive Cardiology, 2022, 29, 1200-1201.	1.8	5
8	Impact of Diabetes Mellitus and Its Comorbidities on Elderly Patients Hospitalized in Internal Medicine Wards: Data from the RePoSi Registry. Healthcare (Switzerland), 2022, 10, 86.	2.0	10
9	Vaccine-induced immune thrombotic thrombocytopenia with atypical vein thrombosis: Implications for clinical practice. Phlebology, 2022, , 026835552110689.	1.2	4
10	Histological and immunohistochemical findings in a fatal case of thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. Pathology Research and Practice, 2022, 231, 153796.	2.3	5
11	Managing prostatic illness in persons with haemophilia. Haemophilia, 2022, 28, 369-370.	2.1	0
12	Pharmaceutical pricing in Europe: time to take the right direction. Internal and Emergency Medicine, 2022, 17, 945-948.	2.0	5
13	An ecological alliance against air pollution and cardiovascular disease. , 2022, 1, 19-23.		0
14	Gene transfer in hemophilia A: not cogent yet. , 2022, 1, 7-8.		2
15	What changed in the Italian internal medicine and geriatric wards during the lockdown. European Journal of Internal Medicine, 2021, 84, 97-100.	2.2	0
16	Intelligent game engines for home exercises (exergames) in boys with haemophilia. Haemophilia, 2021, 27, e151-e154.	2.1	5
17	Pharmacist-driven medication recognition/ reconciliation in older medical patients. European Journal of Internal Medicine, 2021, 83, 39-44.	2.2	10
18	Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry. Internal and Emergency Medicine, 2021, 16, 389-400.	2.0	18

#	Article	IF	Citations
19	The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of the REPOSI registry. Age and Ageing, 2021, 50, 498-504.	1.6	1
20	Community and hospital pharmacists in Europe: encroaching on medicine?. Internal and Emergency Medicine, 2021, 16, 7-10.	2.0	3
21	Improving primary care in Europe beyond COVID-19: from telemedicine to organizational reforms. Internal and Emergency Medicine, 2021, 16, 255-258.	2.0	26
22	Authorsâ€™ Reply to Brunetti et al. â€œPotentially Inappropriate Medications, Drugâ€“Drug Interactions, and Anticholinergic Burden in Elderly Hospitalized Patients: Does an Association Exist with Post-Discharge Health Outcomes?â€• Drugs and Aging, 2021, 38, 93-94.	2.7	1
23	IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A. British Journal of Haematology, 2021, 192, 621-625.	2.5	1
24	Von Willebrand disease type 2N: An update. Journal of Thrombosis and Haemostasis, 2021, 19, 909-916.	3.8	14
25	Noise and air pollution as triggers of hypertension. European Heart Journal, 2021, 42, 2085-2087.	2.2	23
26	Sustainable and personalized nutrition: From earth health to public health. European Journal of Internal Medicine, 2021, 86, 12-16.	2.2	10
27	Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry. Acta Diabetologica, 2021, 58, 1225-1236.	2.5	6
28	Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A. Haemophilia, 2021, 27, e441-e449.	2.1	1
29	Perspective â€“ The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021. Blood Reviews, 2021, 50, 100849.	5.7	4
30	Post-mortem findings in vaccine-induced thrombotic thombocytopenia. Haematologica, 2021, 106, 2291-2293.	3.5	47
31	COVID-19 Vaccine and Death: Causality Algorithm According to the WHO Eligibility Diagnosis. Diagnostics, 2021, 11, 955.	2.6	49
32	Bleeding Disorders in Primary Fibrinolysis. International Journal of Molecular Sciences, 2021, 22, 7027.	4.1	8
33	Use of Lipid-Lowering Drugs and Associated Outcomes According to Health State Profiles in Hospitalized Older Patients. Clinical Interventions in Aging, 2021, Volume 16, 1251-1264.	2.9	7
34	Comparison of quality of life, and emotional and functional profiles in older people with and without severe haemophilia. Haemophilia, 2021, 27, e525-e529.	2.1	1
35	Association between air temperature, air pollution and hospital admissions for pulmonary embolism and venous thrombosis in Italy. European Journal of Internal Medicine, 2021, , .	2.2	5
36	Pharmaceutical patenting in the European Union: reform or riddance. Internal and Emergency Medicine, 2021, , 1.	2.0	2

#	Article	IF	Citations
37	Prophylactic management of patients with von Willebrand disease. Therapeutic Advances in Hematology, 2021, 12, 204062072110640.	2.5	5
38	Thrombotic thrombocytopenic purpura and other immune mediated blood disorders following SARS-CoV-2 vaccination. Haematologica, 2021, , .	3.5	0
39	Comorbidity does not mean clinical complexity: evidence from the RePoSI register. Internal and Emergency Medicine, 2020, 15, 621-628.	2.0	18
40	Use and prescription appropriateness of drugs for peptic ulcer and gastrooesophageal reflux disease in hospitalized older people. European Journal of Clinical Pharmacology, 2020, 76, 459-465.	1.9	13
41	The dark age of Italian general practice research â€“ An Italian matter. European Journal of Internal Medicine, 2020, 73, 98-99.	2.2	4
42	Pain and Frailty in Hospitalized Older Adults. Pain and Therapy, 2020, 9, 727-740.	3.2	22
43	SARS-CoV2 vertical transmission with adverse effects on the newborn revealed through integrated immunohistochemical, electron microscopy and molecular analyses of Placenta. EBioMedicine, 2020, 59, 102951.	6.1	193
44	The never ending success story of tranexamic acid in acquired bleeding. Haematologica, 2020, 105, 1201-1205.	3.5	27
45	Potentially Inappropriate Medications, Drugâ€“Drug Interactions, and Anticholinergic Burden in Elderly Hospitalized Patients: Does an Association Exist with Post-Discharge Health Outcomes?. Drugs and Aging, 2020, 37, 585-593.	2.7	27
46	Acquired von Willebrand syndrome: focused for hematologists. Haematologica, 2020, 105, 2032-2037.	3.5	67
47	Witnessing the 1980s. Haemophilia, 2020, 26, 373-374.	2.1	0
48	Hemophilia therapy: the future has begun. Haematologica, 2020, 105, 545-553.	3.5	132
49	Conflicts of interest in medicine: a never-ending story. Internal and Emergency Medicine, 2020, 15, 357-359.	2.0	6
50	Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A. Expert Opinion on Investigational Drugs, 2020, 29, 303-309.	4.1	16
51	Defensive medicine: Everything and its opposite. European Journal of Internal Medicine, 2020, 74, 117-118.	2.2	6
52	Direct oral anticoagulants and cirrhosis: More evidence still needed for efficacy and safety in portal vein thrombosis. Vascular Pharmacology, 2019, 113, 92-93.	2.1	5
53	Novel evidence for a greater burden of ambient air pollution on cardiovascular disease. Haematologica, 2019, 104, 2349-2357.	3.5	88
54	AGING WITH HEMOPHILIA: THE CHALLENGE OF APPROPRIATE DRUG PRESCRIPTION. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019056.	1.3	7

#	Article	IF	Citations
55	Drugâ€“drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients. European Journal of Internal Medicine, 2019, 65, 51-57.	2.2	24
56	Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study. Medical Principles and Practice, 2019, 28, 501-508.	2.4	5
57	New therapies for von Willebrand disease. Hematology American Society of Hematology Education Program, 2019, 2019, 590-595.	2.5	7
58	New therapies for von Willebrand disease. Blood Advances, 2019, 3, 3481-3487.	5.2	29
59	Sex-Differences in the Pattern of Comorbidities, Functional Independence, and Mortality in Elderly Inpatients: Evidence from the RePoSI Register. Journal of Clinical Medicine, 2019, 8, 81.	2.4	21
60	Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfusion, 2019, 17, 479-486.	0.4	53
61	Telemedicine and telerehabilitation: current and forthcoming applications in haemophilia. Blood Transfusion, 2019, 17, 385-390.	0.4	18
62	Use of desmopressin in the treatment of hemophilia A: towards a golden jubilee. Haematologica, 2018, 103, 379-381.	3.5	2
63	Prognostic relevance of glomerular filtration rate estimation obtained through different equations in hospitalized elderly patients. European Journal of Internal Medicine, 2018, 54, 60-64.	2.2	4
64	Primary hyperfibrinolysis: Facts and fancies. Thrombosis Research, 2018, 166, 71-75.	1.7	18
65	Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. Journal of Thrombosis and Haemostasis, 2018, 16, 778-790.	3.8	23
66	How to win space in medical journals: Bits and tips. European Journal of Internal Medicine, 2018, 50, 1-2.	2.2	0
67	Viral safety of coagulation factor concentrates: memoirs from an insider. Journal of Thrombosis and Haemostasis, 2018, 16, 630-633.	3.8	8
68	The importance of ABO blood group in pharmacokinetic studies in haemophilia A. Haemophilia, 2018, 24, e122-e123.	2.1	5
69	Risk factors for three-month mortality after discharge in a cohort of non-oncologic hospitalized elderly patients: Results from the REPOSI study. Archives of Gerontology and Geriatrics, 2018, 74, 169-173.	3.0	14
70	Comorbidities in persons with haemophilia aged 60 years or more compared with ageâ€matched people from the general population. Haemophilia, 2018, 24, e6-e10.	2.1	15
71	A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies. Expert Review of Hematology, 2018, 11, 87-97.	2.2	14
72	Disability, and not diabetes, is a strong predictor of mortality in oldest old patients hospitalized with pneumonia. European Journal of Internal Medicine, 2018, 54, 53-59.	2.2	19

#	Article	IF	Citations
73	Polypharmacy in older adults with severe haemophilia. Haemophilia, 2018, 24, e1-e3.	2.1	4
74	Ageing successfully with haemophilia: A multidisciplinary programme. Haemophilia, 2018, 24, 57-62.	2.1	21
75	Polypharmacy in older people: lessons from 10Âyears of experience with the REPOSIÂregister. Internal and Emergency Medicine, 2018, 13, 1191-1200.	2.0	45
76	Miracle of haemophilia drugs: Personal views about a few main players. Haemophilia, 2018, 24, 557-562.	2.1	21
77	Mitigation of air pollution by greenness: A narrative review. European Journal of Internal Medicine, 2018, 55, 1-5.	2.2	55
78	Rate and appropriateness of polypharmacy in older patients with hemophilia compared with ageâ€matched controls. Haemophilia, 2018, 24, 726-732.	2.1	7
79	More on air pollution and venous thromboembolism. European Journal of Internal Medicine, 2017, 37, e11.	2.2	1
80	Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa). Expert Opinion on Drug Safety, 2017, 16, 405-410.	2.4	4
81	Laboratory monitoring of replacement therapy for major surgery in von Willebrand disease. Haemophilia, 2017, 23, 182-187.	2.1	18
82	Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF. International Journal of Cardiology, 2017, 232, 98-104.	1.7	16
83	Reply to the letter by Iorio. Haemophilia, 2017, 23, e248-e249.	2.1	3
84	Antipsychotic prescription and mortality in hospitalized older persons. Psychogeriatrics, 2017, 17, 397-405.	1.2	9
85	Progress in the contemporary management of hemophilia: The new issue of patient aging. European Journal of Internal Medicine, 2017, 43, 16-21.	2.2	26
86	Involvement of the IgEâ€basophil system and mild complement activation in haemophilia B with antiâ€factor IX neutralizing antibodies and anaphylaxis. Haemophilia, 2017, 23, e348-e353.	2.1	8
87	Homeopathy provided by a national health service: Only in Italy?. European Journal of Internal Medicine, 2017, 41, 1-2.	2.2	2
88	SIPPET: methodology, analysis and generalizability. Haemophilia, 2017, 23, 353-361.	2.1	27
89	Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. Blood, 2017, 129, 1245-1250.	1.4	41
90	Relationship between atrial fibrillation and cognitive decline in individuals aged 80 and older. European Journal of Internal Medicine, 2017, 46, 6-10.	2.2	16

#	Article	IF	Citations
91	Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. Blood, 2017, 130, 1757-1759.	1.4	44
92	Management of Hemophilia in Older Patients. Drugs and Aging, 2017, 34, 881-889.	2.7	6
93	Use of non-steroidal anti-inflammatory drugs and analgesics in a cohort of hospitalized elderly patients: Results from the REPOSI study. European Journal of Internal Medicine, 2017, 38, e11-e12.	2.2	1
94	Prognostic value of degree and types of anaemia on clinical outcomes for hospitalised older patients. Archives of Gerontology and Geriatrics, 2017, 69, 21-30.	3.0	17
95	Air pollution levels and cardiovascular health: Low is not enough. European Journal of Preventive Cardiology, 2017, 24, 1851-1853.	1.8	15
96	Health Effects of Ambient Air Pollution in Developing Countries. International Journal of Environmental Research and Public Health, 2017, 14, 1048.	2.6	319
97	The increased demand for plasma-derived factor VIII in Italy. Blood Transfusion, 2017, 15, 279-280.	0.4	7
98	Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A. Journal of Thrombosis and Haemostasis, 2016, 14, 1330-1336.	3.8	17
99	Ndufc2 Gene Inhibition Is Associated With Mitochondrial Dysfunction and Increased Stroke Susceptibility in an Animal Model of Complex Human Disease. Journal of the American Heart Association, 2016, 5, .	3.7	43
100	The safety of pharmacologic options for the treatment of persons with hemophilia. Expert Opinion on Drug Safety, 2016, 15, 1391-1400.	2.4	12
101	Defining Aging Phenotypes and Related Outcomes: Clues to Recognize Frailty in Hospitalized Older Patients. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 72, glw188.	3.6	41
102	Predictors of clinical events occurring during hospital stay among elderly patients admitted to medical wards in Italy. European Journal of Internal Medicine, 2016, 32, 38-42.	2.2	6
103	Innovative Pharmacological Therapies for the Hemophilias Not Based on Deficient Factor Replacement. Seminars in Thrombosis and Hemostasis, 2016, 42, 526-532.	2.7	32
104	Direct oral anticoagulants and venous thromboembolism. European Respiratory Review, 2016, 25, 295-302.	7.1	27
105	Therapeutic Duplicates in a Cohort of Hospitalized Elderly Patients: Results from the REPOSI Study. Drugs and Aging, 2016, 33, 647-654.	2.7	4
106	Von Willebrand factor (VonvendiÂ®): the first recombinant product licensed for the treatment of von Willebrand disease. Expert Review of Hematology, 2016, 9, 825-830.	2.2	32
107	Uncertain thrombophilia markers. Thrombosis and Haemostasis, 2016, 115, 25-30.	3.4	32
108	Association between particulate air pollution and venous thromboembolism: A systematic literature review. European Journal of Internal Medicine, 2016, 27, 10-13.	2.2	43

#	Article	IF	Citations
109	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget, 2016, 7, 80083-80090.	1.8	24
110	Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clinical Advances in Hematology and Oncology, 2016, 14 Suppl 11, 2-15.	0.3	23
111	Half-life extension technologies for haemostatic agents. Thrombosis and Haemostasis, 2015, 113, 165-176.	3.4	29
112	Factor VIII products in haemophilia A: one size fits all?. Thrombosis and Haemostasis, 2015, 113, 911-914.	3.4	14
113	Classic thrombophilic gene variants. Thrombosis and Haemostasis, 2015, 114, 885-889.	3.4	93
114	Management of Bleeding Associated with New Oral Anticoagulants. Seminars in Thrombosis and Hemostasis, 2015, 41, 788-801.	2.7	17
115	Gender difference in drug use in hospitalized elderly patients. European Journal of Internal Medicine, 2015, 26, 483-490.	2.2	25
116	Recombinant porcine factor <scp>VIII</scp>: a new instalment of a long story. Haemophilia, 2015, 21, 149-151.	2.1	3
117	Impact on human health of climate changes. European Journal of Internal Medicine, 2015, 26, 1-5.	2.2	107
118	The stigma of low opioid prescription in the hospitalized multimorbid elderly in Italy. Internal and Emergency Medicine, 2015, 10, 305-313.	2.0	7
119	Introduction and overview. Blood Reviews, 2015, 29, S1-S3.	5.7	0
120	Effects on health of air pollution: a narrative review. Internal and Emergency Medicine, 2015, 10, 657-662.	2.0	200
121	Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study. European Journal of Internal Medicine, 2015, 26, 243-249.	2.2	14
122	Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. European Journal of Internal Medicine, 2015, 26, 330-337.	2.2	25
123	Understanding organ dysfunction in thrombotic thrombocytopenic purpura. Intensive Care Medicine, 2015, 41, 715-718.	8.2	17
124	The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring. Thrombosis Research, 2015, 136, 851-854.	1.7	27
125	Appropriateness of antithrombotic prophylaxis in the oldest old with non-valvular atrial fibrillation: ARAPACIS and REPOSI. European Journal of Internal Medicine, 2015, 26, e47-e48.	2.2	1
126	The Health and Economic Burden of Air Pollution. American Journal of Medicine, 2015, 128, 931-932.	1.5	24

#	Article	IF	Citations
127	Under-detection of delirium and impact of neurocognitive deficits on in-hospital mortality among acute geriatric and medical wards. European Journal of Internal Medicine, 2015, 26, 696-704.	2.2	65
128	Gastrointestinal angiodysplasia and bleeding in von Willebrand disease. Thrombosis and Haemostasis, 2014, 112, 427-431.	3.4	60
129	The real value of thrombophilia markers in identifying patients at high risk of venous thromboembolism. Expert Review of Hematology, 2014, 7, 757-765.	2.2	19
130	Reply to: The importance and challenge of pediatric trials of hemophilia drugs. Nature Medicine, 2014, 20, 466-466.	30.7	3
131	Pediatric requirements in Europe stymie help for hemophilia. Nature Medicine, 2014, 20, 117-117.	30.7	8
132	Making clinical decisions on the basis of RODIN. Haemophilia, 2014, 20, e174-e175.	2.1	0
133	Emerging drugs for hemophilia B. Expert Opinion on Emerging Drugs, 2014, 19, 407-414.	2.4	4
134	Integrated postural analysis in children with haemophilia. Haemophilia, 2014, 20, 263-267.	2.1	12
135	Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. Internal and Emergency Medicine, 2014, 9, 723-734.	2.0	121
136	Haematology clinic: Haemophilia A. Hematology, 2014, 19, 181-182.	1.5	11
137	Prognostic value of estimated glomerular filtration rate in hospitalized elderly patients. Internal and Emergency Medicine, 2014, 9, 735-747.	2.0	16
138	Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. European Journal of Internal Medicine, 2014, 25, 847-852.	2.2	1
139	Novel investigations on the protective role of the <scp>FVIII</scp>/<scp>VWF</scp> complex in inhibitor development. Haemophilia, 2014, 20, 2-16.	2.1	17
140	Prevalence of potentially inappropriate medications and risk of adverse clinical outcome in a cohort of hospitalized elderly patients: results from the REPOSI Study. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 511-515.	1.5	59
141	Gender-differences in disease distribution and outcome in hospitalized elderly: Data from the REPOSI study. European Journal of Internal Medicine, 2014, 25, 617-623.	2.2	75
142	Inhibitor eradication with rituximab in haemophilia: where do we stand?. British Journal of Haematology, 2014, 165, 600-608.	2.5	51
143	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2014, 61, 148-154.	3.7	149
144	Prescription Drug Use Among Older Adults in Italy: A Country-Wide Perspective. Journal of the American Medical Directors Association, 2014, 15, 531.e11-531.e15.	2.5	22

#	Article	IF	Citations
145	The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood, 2014, 123, 4037-4044.	1.4	123
146	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood, 2014, 124, 1715-1726.	1.4	288
147	Haemophilia Centre Certification Systems: optional or optimal choice for healthcare systems?. Blood Transfusion, 2014, 12 Suppl 3, s492-4.	0.4	0
148	The European standards of Haemophilia Centres. Blood Transfusion, 2014, 12 Suppl 3, s525-30.	0.4	12
149	The methodology for defining the European standards for the certification of Haemophilia Centres in Europe. Blood Transfusion, 2014, 12 Suppl 3, s519-24.	0.4	4
150	A certification/accreditation model for Haemophilia Centres in Italy. Blood Transfusion, 2014, 12 Suppl 3, s505-9.	0.4	6
151	Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia, 2013, 19, 76-81.	2.1	99
152	Association of Anticholinergic Burden with Cognitive and Functional Status in a Cohort of Hospitalized Elderly: Comparison of the Anticholinergic Cognitive Burden Scale and Anticholinergic Risk Scale. Drugs and Aging, 2013, 30, 103-112.	2.7	140
153	Is haemophilia B less severe than haemophilia A?. Haemophilia, 2013, 19, 499-502.	2.1	61
154	Thromboprophylaxis in the oldest old with atrial fibrillation: Between Scylla and Charybdis. European Journal of Internal Medicine, 2013, 24, 285-287.	2.2	12
155	Investigational drugs for coagulation disorders. Expert Opinion on Investigational Drugs, 2013, 22, 945-953.	4.1	12
156	Von Willebrand diseaseâ€associated angiodysplasia: a few answers, still many questions. British Journal of Haematology, 2013, 161, 177-182.	2.5	68
157	Evolution of the European guidelines for the clinical development of factor VIII products: little progress towards improved patient management. Haemophilia, 2013, 19, 344-348.	2.1	11
158	Drugâ€“drug interactions in a cohort of hospitalized elderly patients. Pharmacoepidemiology and Drug Safety, 2013, 22, 1054-1060.	1.9	53
159	Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood, 2013, 122, 648-657.	1.4	120
160	Acquired haemophilia A: A 2013 update. Thrombosis and Haemostasis, 2013, 110, 1114-1120.	3.4	103
161	Liver disease, coagulopathies and transfusion therapy. Blood Transfusion, 2013, 11, 32-6.	0.4	26
162	Plasma-derived medicinal products: demand and clinical use. Blood Transfusion, 2013, 11 Suppl 4, s2-5.	0.4	4

#	Article	IF	Citations
163	The demand for factor VIII and for factor IX and the toll fractionation product surplus management. Blood Transfusion, 2013, 11 Suppl 4, s64-76.	0.4	12
164	Present and future challanges in the treatment of haemophilia: a clinician's perspective. Blood Transfusion, 2013, 11 Suppl 4, s77-81.	0.4	20
165	Recombinant factor VIIa as haemostatic therapy in advanced liver disease. Blood Transfusion, 2013, 11, 487-90.	0.4	4
166	Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials. Blood Transfusion, 2013, 11, 533-40.	0.4	14
167	Management of antithrombotic therapy for acute coronary syndromes and atrial fibrillation in patients with hemophilia. Expert Opinion on Pharmacotherapy, 2012, 13, 505-510.	1.8	20
168	Getting rid of refractory hemophilia. Blood, 2012, 119, 1326-1327.	1.4	1
169	How we choose factor VIII to treat hemophilia. Blood, 2012, 119, 4108-4114.	1.4	74
170	Air pollution and cardiovascular disease. Thrombosis Research, 2012, 129, 230-234.	1.7	91
171	Healthâ€related quality of life and psychological wellâ€being in elderly patients with haemophilia. Haemophilia, 2012, 18, 345-352.	2.1	29
172	Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia, 2012, 18, e173-87.	2.1	88
173	The role of natural VWF/FVIII complex concentrates in contemporary haemophilia care: a guideline for the next decade. Haemophilia, 2012, 18, 2-7.	2.1	10
174	Clinical governance: many fancies, very few facts. Internal and Emergency Medicine, 2012, 7, 3-4.	2.0	3
175	Hemostatic defects in liver and renal dysfunction. Hematology American Society of Hematology Education Program, 2012, 2012, 168-73.	2.5	15
176	Hemostatic defects in liver and renal dysfunction. Hematology American Society of Hematology Education Program, 2012, 2012, 168-173.	2.5	48
177	ADAMTS13 Content of Plasma-Derived Factor VIII-Von Willebrand Factor Concentrates. Blood, 2012, 120, 3383-3383.	1.4	1
178	Old and new anticoagulant drugs: A minireview. Annals of Medicine, 2011, 43, 116-123.	3.8	48
179	The Coagulopathy of Chronic Liver Disease. New England Journal of Medicine, 2011, 365, 147-156.	27.0	1,171
180	Multiple Diseases and Polypharmacy in the Elderly: Challenges for the Internist of the Third Millennium. Journal of Comorbidity, 2011, 1, 28-44.	3.9	192

#	Article	IF	Citations
181	Thrombogenicity and cardiovascular effects of ambient air pollution. Blood, 2011, 118, 2405-2412.	1.4	167
182	Treatment of haemophilia: building on strength in the third millennium. Haemophilia, 2011, 17, 1-24.	2.1	16
183	A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). Journal of Thrombosis and Haemostasis, 2011, 9, 700-710.	3.8	390
184	Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. European Journal of Clinical Pharmacology, 2011, 67, 507-519.	1.9	255
185	Fine particulate: it matters. Journal of Thrombosis and Haemostasis, 2010, 8, 659-661.	3.8	10
186	Red cells playing as activated platelets in thalassemia intermedia. Journal of Thrombosis and Haemostasis, 2010, 8, 2149-2151.	3.8	23
187	Efficacy and safety of highly purified, doubly virusâ€inactivated VWF/FVIII concentrates in inherited von Willebrandâ€™s disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score. Haemophilia, 2010, 16, 101-110.	2.1	39
188	Coâ€morbidities and quality of life in elderly persons with haemophilia. British Journal of Haematology, 2010, 148, 522-533.	2.5	90
189	Aspirin as antiplatelet agent in diabetes: Cons. European Journal of Internal Medicine, 2010, 21, 154-156.	2.2	1
190	Mechanism of hemostasis defects and management of bleeding in patients with acute coronary syndromes. European Journal of Internal Medicine, 2010, 21, 254-259.	2.2	9
191	Autoimmune hemophilia at rescue. Haematologica, 2009, 94, 459-461.	3.5	9
192	Activated Partial Thromboplastin Time. Scandinavian Journal of Haematology, 2009, 25, 308-317.	0.0	8
193	von Willebrand disease in the 21st century: current approaches and new challenges. Haemophilia, 2009, 15, 1154-1158.	2.1	11
194	Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. Journal of Thrombosis and Haemostasis, 2009, 7, 780-786.	3.8	122
195	FactorÂVIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophiliaÂA patients with highâ€responding inhibitors. Journal of Thrombosis and Haemostasis, 2009, 7, 1809-1815.	3.8	103
196	Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.. Blood, 2009, 114, 3154-3154.	1.4	0
197	Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfusion, 2009, 7, 117-26.	0.4	63
198	Desmopressin: an historical introduction. Haemophilia, 2008, 14, 1-4.	2.1	12

#	Article	IF	Citations
199	Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No. Journal of Thrombosis and Haemostasis, 2008, 6, 1450-1452.	3.8	8
200	Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia, 2008, 14, 444-453.	2.1	88
201	Back to the future: a recent history of haemophilia treatment. Haemophilia, 2008, 14, 10-18.	2.1	137
202	Understanding hemostasis and thrombosis : The lesson learnt from natural models. Japanese Journal of Thrombosis and Hemostasis, 2008, 19, 85-91.	0.1	0
203	Clinical use of Haemate(R) P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. Haematologica, 2007, 92, 944-951.	3.5	85
204	Prevention and Treatment of Major Blood Loss. New England Journal of Medicine, 2007, 356, 2301-2311.	27.0	445
205	Reply:. Hepatology, 2007, 45, 832-833.	7.3	1
206	Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia, 2007, 13, 373-379.	2.1	81
207	Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	2.1	90
208	Thrombosis and bleeding disorders outside Western countries. Journal of Thrombosis and Haemostasis, 2007, 5, 68-72.	3.8	8
209	Treatment of severe von Willebrand disease with a highâ€purity von Willebrand factor concentrate (WilfactinÂ®): a prospective study of 50 patients. Journal of Thrombosis and Haemostasis, 2007, 5, 1115-1124.	3.8	111
210	von Willebrand factor/factor VIII concentrate (HaemateÂ® P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. Journal of Thrombosis and Haemostasis, 2007, 5, 1420-1430.	3.8	118
211	Shortâ€term effects of air pollution on cardiovascular diseases: outcomes and mechanisms. Journal of Thrombosis and Haemostasis, 2007, 5, 2169-2174.	3.8	115
212	Editorial. Journal of Thrombosis and Haemostasis, 2006, 4, 1-2.	3.8	10
213	Need for randomized trials in hemophilia. Journal of Thrombosis and Haemostasis, 2006, 4, 501-502.	3.8	12
214	Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No. Journal of Thrombosis and Haemostasis, 2006, 4, 721-723.	3.8	82
215	Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. Journal of Thrombosis and Haemostasis, 2006, 4, 2103-2114.	3.8	1,061
216	Non-Sense-Mediated mRNA Decay in ADAMTS13 Gene Caused by 29 Nucleotide Deletion.. Blood, 2006, 108, 1061-1061.	1.4	0

#	Article	IF	Citations
217	ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood, 2005, 106, 1262-1267.	1.4	275
218	Thrombolytic therapy in acute myocardial infarction. Journal of Thrombosis and Haemostasis, 2005, 3, 2806-2807.	3.8	0
219	Localization and Function of Platelet ADAMTS-13.. Blood, 2005, 106, 3967-3967.	1.4	0
220	Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. British Journal of Haematology, 2004, 126, 213-218.	2.5	99
221	Ilsley Ingram. Journal of Thrombosis and Haemostasis, 2004, 2, 1219-1219.	3.8	0
222	Treatment of von Willebrand's Disease. New England Journal of Medicine, 2004, 351, 683-694.	27.0	464
223	Recessively inherited coagulation disorders. Blood, 2004, 104, 1243-1252.	1.4	479
224	The International Society for Thrombosis and Haemostasis owns its official journal: the future has begun!. Journal of Thrombosis and Haemostasis, 2003, 1, 1-2.	3.8	33
225	Consistency of ADAMTS-13 activity assays: a moderately optimistic view. Journal of Thrombosis and Haemostasis, 2003, 1, 1880-1881.	3.8	8
226	AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider. Journal of Thrombosis and Haemostasis, 2003, 1, 2065-2069.	3.8	24
227	Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood, 2003, 102, 2358-2363.	1.4	351
228	Overview of Bleeding in Cancer Patients. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 44-45.	0.3	6
229	Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). Haematologica, 2003, 88, 454-8.	3.5	37
230	Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica, 2003, 88, 914-8.	3.5	85
231	Venous thrombosis: the history of knowledge. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2002, 32, 209-212.	0.3	24
232	Venous thromboembolism in von Willebrand disease. Thrombosis and Haemostasis, 2002, 88, 378-9.	3.4	41
233	How I treat patients with von Willebrand disease. Blood, 2001, 97, 1915-1919.	1.4	157
234	Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood, 2001, 98, 2730-2735.	1.4	488

#	Article	IF	Citations
235	Venous thrombosis and anticoagulant therapy. British Journal of Haematology, 2001, 114, 258-270.	2.5	31
236	Coexistence of a novel homozygous nonsense mutation in exon 13 of the factor V gene with the homozygous Leiden mutation in two unrelated patients with severe factor V deficiency. British Journal of Haematology, 2001, 114, 871-874.	2.5	20
237	The Hemophilias â€" From Royal Genes to Gene Therapy. New England Journal of Medicine, 2001, 344, 1773-1779.	27.0	936
238	Use of Prophylaxis to Prevent Complications of Hemophilia. Advances in Experimental Medicine and Biology, 2001, 489, 59-64.	1.6	13
239	Treatment of von Willebrand disease. Thrombosis and Haemostasis, 2001, 86, 149-53.	3.4	10
240	The search for the causes of myocardial infarction. Introduction. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2001, 2, 489.	0.1	0
241	Autoimmune bleeding disorders in cancer patients. Haemostasis, 2001, 31 Suppl 1, 45-6.	0.0	0
242	Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Haemophilia, 2000, 6, 60-67.	2.1	104
243	A novel two base pair deletion in the factor V gene associated with severe factor V deficiency. British Journal of Haematology, 2000, 111, 1240-1246.	2.5	1
244	The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. British Journal of Haematology, 2000, 111, 1223-1229.	2.5	6
245	Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. British Journal of Haematology, 2000, 111, 1236-1239.	2.5	91
246	Aspects of the Clinical Management of Hereditary Thrombophilia: A Personal Perspective. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2000, 30, 11-15.	0.3	3
247	Choice of replacement therapy for hemophilia: recombinant products only?. The Hematology Journal, 2000, 1, 72-76.	1.4	6
248	Gly319â€ƒâ†'â€ƒArg substitution in the dysfunctional prothrombin Segovia. British Journal of Haematology, 1999, 105, 667-669.	2.5	12
249	Thrombotic thrombocytopenic purpura: a simpler diagnosis at last?. Thrombosis and Haemostasis, 1999, 82, 1380-1.	3.4	3
250	Treatment of von Willebrand disease. International Journal of Clinical and Laboratory Research, 1998, 28, 211-214.	1.0	7
251	Treatment of von Willebrand disease. Haemophilia, 1998, 4, 661-664.	2.1	30
252	Hemostatic Drugs. New England Journal of Medicine, 1998, 339, 245-253.	27.0	581

#	Article	IF	Citations
253	Treatment of von Willebrand Disease. Hematology, 1998, 3, 339-346.	1.5	15
254	Different Risks of Thrombosis in Four Coagulation Defects Associated With Inherited Thrombophilia: A Study of 150 Families. Blood, 1998, 92, 2353-2358.	1.4	378
255	A Common Mutation in the Methylenetetrahydrofolate Reductase Gene (C677T) Increases the Risk for Deep-Vein Thrombosis in Patients With Mutant Factor V (Factor V:Q 506). Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1662-1666.	2.4	161
256	Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: The First 20 Years. Blood, 1997, 90, 2515-2521.	1.4	466
257	Partial inhibition of platelet aggregation by nebulized pentamidine in severe haemophiliacs. Haemophilia, 1997, 3, 31-34.	2.1	1
258	Clinical manifestations in 28 Italian and Iranian patients with severe factor VII deficiency. Haemophilia, 1997, 3, 242-246.	2.1	92
259	Resistance to activated protein C in unselected patients with arterial and venous thrombosis. American Journal of Hematology, 1997, 55, 59-64.	4.1	19
260	Deficiency of (33P)2MeS-ADP Binding Sites on Platelets with Secretion Defect, Normal Granule Stores and Normal Thromboxane A2 Production. Thrombosis and Haemostasis, 1997, 77, 0986-0990.	3.4	76
261	Transfusion Requirements Are Correlated with the Degree of Proteolysis of von Willebrand Factor during Orthotopic Liver Transplantation. Thrombosis and Haemostasis, 1997, 78, 813-819.	3.4	6
262	High Frequency of the C677T Mutation in the Methylenetetrahydrofolate Reductase (MTHFR) Gene in Northern Italy. Thrombosis and Haemostasis, 1997, 78, 963-964.	3.4	43
263	Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood, 1997, 90, 2515-21.	1.4	88
264	Treatment of von Willebrand's disease. Journal of Internal Medicine Supplement, 1997, 740, 129-32.	0.0	1
265	Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukaemia by treatment with allâ€transâ€retinoic acid. British Journal of Haematology, 1996, 92, 733-739.	2.5	27
266	William Hewson and the blood which issued last but clotted first: the beginning of the story of desmopressin in haemophilia and vWD. Haemophilia, 1996, 2, 180-183.	2.1	1
267	Hemostasis Abnormalities in Patients with Vascular Dementia and Alzheimerâ€™s Disease. Thrombosis and Haemostasis, 1996, 75, 216-218.	3.4	60
268	Frequency of Factor V Arg506 Gin in Italians. Thrombosis and Haemostasis, 1996, 75, 694-694.	3.4	4
269	Oral Contraceptives Are a Risk Factor for Cerebral Vein Thrombosis. Thrombosis and Haemostasis, 1996, 76, 477-478.	3.4	20
270	B19 Parvovirus Withstands â€œSuper Heatingâ€•in Antihemophilic Concentrates. Thrombosis and Haemostasis, 1996, 76, 821-821.	3.4	7

#	Article	IF	Citations
271	Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. British Journal of Haematology, 1995, 91, 434-444.	2.5	134
272	The knowledge and perception of factor concentrate in persons with haemophilia A. Haemophilia, 1995, 1, 232-235.	2.1	1
273	Viral safety of plasma-derived and recombinant products used in the management of haemophilia A and B. Haemophilia, 1995, 1, 14-20.	2.1	6
274	Effects of Factor VIII Concentrates on the Immune System of Patients with Hemophilia. Thrombosis and Haemostasis, 1995, 74, 437-439.	3.4	7
275	The Effect of Desmopressin on Reducing Blood Loss in Cardiac Surgery â€“ A Meta-Analysis of Double-Blind, Placebo-Controlled Trials. Thrombosis and Haemostasis, 1995, 74, 1064-1070.	3.4	89
276	Very Low Frequency of â€œNormandy Typeâ€•Mutations among Type 1 von Willebrand Disease Families. Thrombosis and Haemostasis, 1995, 73, 324-324.	3.4	4
277	Preliminary In Vivo Evaluation of a Nanofiltered Factor IX Concentrate. Thrombosis and Haemostasis, 1995, 73, 737-738.	3.4	2
278	Risk of Inhibitor Development after Intermediate Purity Coagulation Factor Concentrates: Is It Truly Low?. Thrombosis and Haemostasis, 1995, 74, 997-997.	3.4	3
279	Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor. British Journal of Haematology, 1994, 86, 333-337.	2.5	18
280	Repeated Release of the Tissue Factor Pathway Inhibitor. Thrombosis and Haemostasis, 1994, 72, 327-328.	3.4	6
281	Clinical Evaluation of Viral Safety of Coagulation Factor VIII and IX Concentrates. Vox Sanguinis, 1993, 64, 197-203.	1.5	73
282	Type I von Willebrand disease, subtype â€˜platelet lowâ€™: decreased platelet adhesion can be explained by low synthesis of von Willebrand factor in endothelial cells. British Journal of Haematology, 1993, 83, 88-93.	2.5	26
283	Antiplatelet Agents in Acute Myocardial Infarction and in the Post-infarction Period. Platelets, 1993, 4, 24-25.	2.3	0
284	Pharmacokinetics of Monoclonally-Purified and Recombinant Factor VIII in Patients with Severe von Willebrand Disease. Thrombosis and Haemostasis, 1993, 70, 270-272.	3.4	60
285	Modern Treatment of Hemophilia: From the Shadows Towards the Light. Thrombosis and Haemostasis, 1993, 70, 017-023.	3.4	31
286	Comparison of Functional Assays for Protein S: European Collaborative Study of Patients with Congenital and Acquired Deficiency. Thrombosis and Haemostasis, 1993, 70, 0946-0950.	3.4	34
287	Risk of thromboembolic complications in patients with inflammatory bowel disease. International Journal of Clinical and Laboratory Research, 1992, 21, 165-170.	1.0	48
288	Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). British Journal of Haematology, 1992, 82, 87-93.	2.5	169

#	Article	IF	Citations
289	Sustained correction of the bleeding time in an afibrinogenaemic patient after infusion of fresh frozen plasma. British Journal of Haematology, 1992, 82, 388-390.	2.5	28
290	Intramuscular antiâ€Ð immunoglobulins for home treatment of chronic immune thrombocytopenic purpura. British Journal of Haematology, 1992, 80, 337-340.	2.5	27
291	Immune Status of Asymptomatic HIV-Infected Hemophiliacs: Randomized, Prospective, Two-Year Comparison of Treatment with a High-Purity or an Intermediate-Purity Factor VIII Concentrate. Thrombosis and Haemostasis, 1992, 67, 310-313.	3.4	32
292	The Effect of Instrumentation on Thromboplastin Calibration. Thrombosis and Haemostasis, 1992, 67, 588-589.	3.4	19
293	Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood, 1992, 79, 3130-7.	1.4	20
294	Low Levels of the Anticoagulant Activity of Protein C in Patients with Chronic Renal Insufficiency: an Inhibitor of Protein C Is Present in Uremic Plasma. Thrombosis and Haemostasis, 1991, 66, 420-425.	3.4	28
295	Adverse Effects of Treatment with Porcine Factor VIII. Thrombosis and Haemostasis, 1991, 65, 245-247.	3.4	47
296	Spontaneous platelet aggregation during pregnancy in a patient with von Willebrand disease type IIB can be blocked by monoclonal antibodies to both platelet glycoproteins Ib and IIb/IIIa. British Journal of Haematology, 1990, 75, 86-91.	2.5	2
297	Restriction of Polymerase Chain Reaction Products for Carrier. Thrombosis and Haemostasis, 1990, 63, 527-528.	3.4	2
298	Antibody to Hepatitis G Mrus after a Vapour-Heated Factor Vlll Goncentrate. Thrombosis and Haemostasis, 1990, 64, 232-234.	3.4	26
299	Subcutaneous Desmopressin (DDAVP) Shortens the Prolonged Bleeding Time in Patients with Liver Cirrhosis. Thrombosis and Haemostasis, 1990, 64, 358-360.	3.4	45
300	Dissociated antibody responses to the s and pre-s2 regions of the hepatitis b virus after vaccination in hemophiliacs. Journal of Medical Virology, 1989, 28, 156-158.	5.0	5
301	Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia. American Journal of Hematology, 1989, 31, 32-35.	4.1	59
302	Type II H von willebrand disease: New structural abnormality of plasma and platelet von willebrand factor in a patient with prolonged bleeding time and borderline levels of ristocetin cofactor activity. American Journal of Hematology, 1989, 32, 287-293.	4.1	18
303	Monoclonal Antibodies Directed to the Calcium-Free Conformation of Human Protein S. Thrombosis and Haemostasis, 1989, 62, 708-714.	3.4	12
304	Familial Dysfunction of Protein S. Thrombosis and Haemostasis, 1989, 62, 763-766.	3.4	34
305	Fibrin(ogen) Peptides in Early Breast Cancer. Thrombosis and Haemostasis, 1989, 62, 819.	3.4	2
306	Antithrombin Milano, Single Amino Acid Substitution at the Reactive Site, Arg393 to Cys. Thrombosis and Haemostasis, 1988, 60, 471-475.	3.4	29

#	Article	IF	Citations
307	EVALUATION OF A FULLY AUTOMATED CENTRIFUGAL ANALYSER FOR ITS PERFORMANCE OF HEMOSTASIS TESTS. , 1987, 58, 0457.		0
308	Combined Use of DNA Probes in First-Trimester Prenatal Diagnosis of Hemophilia A. Thrombosis and Haemostasis, 1987, 58, 988-992.	3.4	4
309	Intravenous and Subcutaneous Administration of Desmopresssin (DDAVP) to Hemophiliacs: Pharmacokinetics and Factor VIII Responses. Thrombosis and Haemostasis, 1987, 58, 1037-1039.	3.4	69
310	Multicenter Comparison of Five Functional and Two Immunological Assays for Protein C. Thrombosis and Haemostasis, 1987, 57, 044-048.	3.4	26
311	Laboratory Screening of Inherited Thrombotic Syndromes. Thrombosis and Haemostasis, 1987, 57, 247-251.	3.4	67
312	Fibrinogens â€œMilano IIâ€• and â€œNaplesâ€• Thrombosis and Haemostasis, 1987, 57, 375-375.	3.4	2
313	Von Willebrand factor contaminating porcine factor VIII concentrate (Hyate: C) causes platelet aggregation. British Journal of Haematology, 1986, 63, 703-711.	2.5	31
314	Fibrinogen Milano II: A Congenital Dysfibrinogenaemia Associated with Juvenile Arterial and Venous Thrombosis. Thrombosis and Haemostasis, 1986, 55, 131-135.	3.4	34
315	Electroblot and Immunoperoxidase Staining for Rapid Screening of the Abnormalities of the Multimeric Structure of von Willebrand Factor in von Willebrandâ€™s Disease. Thrombosis and Haemostasis, 1986, 55, 246-249.	3.4	13
316	Characterization of an Abnormal Antithrombin (Milano 2) with Defective Thrombin Binding. Thrombosis and Haemostasis, 1986, 56, 349-352.	3.4	6
317	Charge heterogeneity of human protein C revealed by isoelectric focusing in immobilized pH gradients. Electrophoresis, 1985, 6, 373-376.	2.4	14
318	ABSENCE OF ANTIBODIES TO AIDS VIRUS IN HAEMOPHILIACS TREATED WITH HEAT-TREATED FACTOR VIII CONCENTRATE. Lancet, The, 1985, 325, 271-272.	13.7	91
319	TRANSMISSION OF NON-A, NON-B HEPATITIS BY HEAT-TREATED FACTOR VIII CONCENTRATE. Lancet, The, 1985, 326, 1-4.	13.7	188
320	Human Platelet Aggregation and Release Reaction Induced by Platelet Activating Factor (PAF-Acether) â€“ Effects of Acetylsalicylic Acid and External Ionized Calcium. Thrombosis and Haemostasis, 1985, 53, 221-224.	3.4	16
321	Hemostatic Functions in Hypoalpha and Hyperbetalipoproteinemias. Thrombosis and Haemostasis, 1983, 50, 624-625.	3.4	5
322	Biochemical and Metabolic Aspects of Platelet Dysfunction in Chronic Myeloproliferative Disorders. Thrombosis and Haemostasis, 1982, 47, 084-089.	3.4	91
323	Health technology assessment for pharmaceuticals in the European Union: what lessons after two decades?. Internal and Emergency Medicine, 0, , .	2.0	0